ThirtyFiveBio
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
99 Park Dr, Abingdon, Oxfordshire, OX14 ...Website
www.30fivebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ThirtyFiveBio
ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors that it is advancing through lead optimization activities. Created by M:M Bio and Canaan Partners, the company has raised $20 million in seed financing to date. ThirtyFiveBio is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK.Explore more
Popular SearchesThirtyFiveBioThirtyFiveBio LtdSIC Code 87,873NAICS Code 54,541Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ThirtyFiveBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ThirtyFiveBio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ThirtyFiveBio has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ThirtyFiveBio launches new products
Check if ThirtyFiveBio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on ThirtyFiveBio recently announced quarterly report
Check out if ThirtyFiveBio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at ThirtyFiveBio
Click to see if ThirtyFiveBio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined ThirtyFiveBio as Masked Content
Find more new buyers
Compare Similar Companies to ThirtyFiveBio
Compare insights from companies similar to ThirtyFiveBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ThirtyFiveBio
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
ThirtyFiveBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ThirtyFiveBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ThirtyFiveBio.
ThirtyFiveBio Tech Stack
A closer look at the technologies used by ThirtyFiveBio
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
ThirtyFiveBio News & Media
ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program with Initial Focus on Inflammatory Gastrointestinal Disease Ulcerative Colitis
Second Prestigious BMC Grant in Under a Year will Enable Creation and Validation of Biomarker-Driven Process for Precisely Selecting Patients Most Likely to Respond to GPR35 Inhibition Company Narrows Initial Therapeutic Focus to Ulcerative Colitis with Precision Medicine Strategy for...ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program for Treatment of Gastrointestinal Disease and Cancers
Prestigious Award Provides Non-Dilutive Funding to Support Preclinical Activities Designed to Enable Translational Studies and Advancement into Clinical Development of First-in-Class GPR35 Inhibitors OXFORD, England, Sept. 13, 2023 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology...ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American Association for Cancer Research (AACR) Annual Meeting 2023
Third Company Created by M:M Bio and Jointly Incubated by Canaan Partners has Raised $20 Million to Date Pioneering a New Precision Medicine Approach to Gastrointestinal Diseases and Cancers through Targeted Inhibition of GPR35 with First-in-Class Small Molecules AACR Presentation to...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ThirtyFiveBio
Sign Up For FreeTo access detailed company insights
ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and... Read More
